Decisions 21st April 2015


At the meeting that took place on 21st April, the folllowing decisions were agreed.

New Drug Requests

Approved

Stercuila and Frangula (Normacol Plus) (TLS Bue)

  • Approved for inclusion onto the formulary

Aclidinium and formoterol (Duaklir Genuair) (TLS Blue)

  • Approved for inclusion onto the formulary.


 

Shared Care Protocols/TLS Change in Status

Rifaximin

  • The JFG agreed for the TLS change to amber 3 months.  A SCP will need to be developed across BNSSG before the change is implemented in the formulary.

Fosfomycin

  • Agreed for the TLS to change to TLS amber (specialist recommendation, no SCP).  A GP may prescribe after recommendation from a microbiologist. 

Pivmecillinam

  • Agreed for the restrictions to be removed so it maybe prescribed in line with antibiotic guidance.

Rheumatology SCPs

  • Updated SCPs agreed.

Stalevo/Sastravi

  • Agreed for the TLS to change to amber (specialist recommendation, no SCP)

Entacapone

  • Agreed for the TLS to change to amber (specialist recommendation, no SCP)

Rasagaline

  • Agreed for the TLS to change to amber (specialist recommendation, no SCP)

Other decisions

Linaclotide

A review of the current prescribing was presented.  The JFG agreed for linaclotide to remain formulary and to remain amber 1 month currently.

 

Overactive Bladder drugs review

A public health review of the literature was presented.  It was agreed for this to be disseminated further and for the plan to work on and agree a BNSSG OAB treatment pathway.

 

These changes are to be made to the formulary website shortly.

Last updated by: on 22-05-2015 11:48